Log in

LON:INSInstem Share Price, Forecast & News

GBX 454
0.00 (0.00 %)
(As of 07/13/2020 01:40 AM ET)
Add
Compare
Today's Range
469.60
Now: GBX 454
469.60
50-Day Range
445
MA: GBX 466.20
530
52-Week Range
340
Now: GBX 454
558
Volume3,192 shs
Average Volume3,909 shs
Market Capitalization£75.70 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Instem plc provides information technology solutions to the life science market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include Provantis, an integrated Windows-based system for organizations and universities that are engaged in non-clinical evaluation studies; submit platform that provides a suite of integrated tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; ALPHADAS, an eSource EDC system for early phase clinical trials; Animal Care Information System, an animal management software solution; Logbook, a repository for information; and Toxicology Resource Planning, a toxicology solution for pharmaceutical, chemical, and contract research laboratory corporations. The company also provides Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Sorcerer Colony Counter for automatic plate counter; Cyto Study Manager, a data acquisition and reporting solution; Ames Study Manager, plate countiner; Sorcerer Colony Counter for automatic plate counter; NOTOCORD-hem and NOTOCORD-fps software platforms to acquire, display, and analyze physiological signals; SEND Explorer, a Web-based application with optional data warehousing capabilities; and SRS data integration platform. It also provides data management, cloud, safety assessment, regulatory information management, solution deployment, and validation services. Additionally, it provides software solutions for extracting intelligence from research and development related healthcare data; and develops, manufactures, and supplies software and hardware products for in vitro study data collection and study management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.
Read More
Instem logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.36 out of 5 stars


Industry, Sector and Symbol

Industry Healthcare Information Services
Sub-IndustryN/A
CUSIPN/A
CIKN/A
Phone+44-1785-825600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£25.72 million
Cash FlowGBX 35.80 per share
Book ValueGBX 101.10 per share

Profitability

Miscellaneous

Employees217
Market Cap£75.70 million
Next Earnings DateN/A
OptionableNot Optionable

Receive INS News and Ratings via Email

Sign-up to receive the latest news and ratings for INS and its competitors with MarketBeat's FREE daily newsletter.

Instem (LON:INS) Frequently Asked Questions

How has Instem's stock been impacted by COVID-19 (Coronavirus)?

Instem's stock was trading at GBX 500 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INS shares have decreased by 9.2% and is now trading at GBX 454. View which stocks have been most impacted by Coronavirus.

Has Instem been receiving favorable news coverage?

Headlines about INS stock have been trending very negative recently, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Instem earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Instem.

Who are some of Instem's key competitors?

What other stocks do shareholders of Instem own?

Who are Instem's key executives?

Instem's management team includes the following people:
  • Mr. Phil J. Reason, CEO & Exec. Director (Age 57)
  • Mr. Nigel John Goldsmith, CFO, Sec. & Exec. Director (Age 57)
  • Ms. Marybeth Thompson, Chief Operating Officer
  • Dr. Gordon Smith Baxter Ph.D., Chief Scientific Officer
  • Mr. Gary Mitchell, VP of Global Marketing

What is Instem's stock symbol?

Instem trades on the London Stock Exchange (LON) under the ticker symbol "INS."

How do I buy shares of Instem?

Shares of INS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Instem's stock price today?

One share of INS stock can currently be purchased for approximately GBX 454.

How big of a company is Instem?

Instem has a market capitalization of £75.70 million and generates £25.72 million in revenue each year. Instem employs 217 workers across the globe.

What is Instem's official website?

The official website for Instem is www.instem.com.

How can I contact Instem?

Instem's mailing address is Diamond Way, Stone Business Park, STONE, ST15 0SD, United Kingdom. The company can be reached via phone at +44-1785-825600.

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.